About Zavante
Zavante is a Healthcare company based in San Diego (United States) founded in 2015, and was acquired by Nabriva in July 2018. US-based, late clinical stage biotech developing IV Fosfomycin for cUTI and other MDR infections. Zavante has raised $80.01 million across 5 funding rounds from investors including Nabriva, Frazier Healthcare Partners and Longitude Capital. Zavante offers products and services including ZOLYD and Clinical Trials Services. Its focus areas include Life Sciences, Infectious Diseases, Drugs and Bacterial. Its legal entity is Zavante Therapeutics, Inc. Its competitors include Paratek Pharma, Spero Therapeutics and Cempra; 3 of its 3 listed competitors have raised funding.
Company details
Zavante is a US-based, late clinical stage biotech developing IV Fosfomycin for cUTI and other MDR infections. Its lead product candidate, ZTI-01, ZOLYD, is a first-in-class injectable antibiotic with a broad spectrum of bactericidal Gram-negative and Gram-positive activity, including activity against most contemporary MDR strains where current therapeutic choices are severely limited. ZTI-01ZOLYD, or IV Fosfomycin, is bactericidal and inhibits bacterial cell wall biogenesis by inactivating the enzyme UDP-N-acetylglucosamine-3-enol-pyruvyl transferase, also known as MurA. As on Aug.2017, ZOLYD is in Phase III trials for the treatment of cUTI, including acute pyelonephritis. The other indications for cUTI are cIAI, ABSSSI, HABPVABP, and others.
- Headquarters San Diego, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website zavante.com
- Social LinkedIn X
- Acquired by Nabriva (Jul 2018)
- Legal Name Zavante Therapeutics, Inc.
Products & Services of Zavante
Zavante offers a comprehensive portfolio of products and services, including ZOLYD and Clinical Trials Services.
Investigational injectable for treating multi-drug resistant bacterial infections
Conducts trials for new antibiotics targeting serious hospital infections
Funding Insights of Zavante
Zavante has successfully raised a total of $80.01M across 5 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $10 million completed in September 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $80.01M
- Total Rounds 5
- Last Round Debt – Conventional — $10M
- First Round $14,200
(May 2015)
- Investors Count 3
All 5 funding rounds of Zavante with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2016 | $10M | Debt – Conventional | – | – | – |
| Mar 2016 | $45M | Series A | – | – | |
| Mar 2016 | $35M | Series A | – | – | |
| Dec 2015 | $10.28M | Debt – Conventional | – | – | – |
| May 2015 | $14,200 | Seed | – | – | – |
4 investors in total: 4 institutional.
Investors in Zavante
Zavante has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include Nabriva, Frazier Healthcare Partners and Longitude Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
Private equity firm focused on life science sector | longitudecapital.com | Menlo Park, United States | ||
PE firm investing in the US | aislingcapital.com | New York, United States | ||
Pleuromutilin antibiotics are developed for MDR infections. | 2006 | nabriva.com | Vienna, Austria |
Investor details for Zavante
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Zavante
4 dated milestones of Zavante across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Zavante is founded.
- Funding First funding round of $14K.
- Funding Latest funding round, Debt – Conventional, of $10.0M.
- Exit Acquired by Nabriva.
Competitors of Zavante
Zavante has 3 listed competitors in our database, 3 of them funded. They include Paratek Pharma, Spero Therapeutics and Cempra.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| paratekpharma.com | 1996 | Boston, United States | $96.48M | 205 | Therapeutics for antimicrobial resistant infections are developed. | |
| sperotherapeutics.com | 2013 | Cambridge, United States | $114.7M | 46 | Therapeutics for drug-resistant bacterial infections are developed. | |
| cempra.com | 2006 | Chapel Hill, United States | $149.5M | 78 | Clinical-stage pharmaceutical company focused on developing antibacterials |
Detailed competitors of Zavante
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Infectious Diseases
3 companies that operate in the same segment as Zavante (Infectious Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 | |
Therapeutics for drug-resistant bacterial infections are developed. | 2013 | Cambridge, Massachusetts, United States | USD 114.7 M | USD 59.62 M | 32 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Zavante
Complete news archive for Zavante
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Zavante
Zavante was founded in 2015.
Zavante is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Zavante is a funded company, having raised a total of $80.01M across 5 funding rounds to date. The company's 1st funding round was a Seed of $14.2K, raised on May 2015.
Zavante is a US-based, late clinical stage biotech developing IV Fosfomycin for cUTI and other MDR infections. Its lead product candidate, ZTI-01, ZOLYD, is a first-in-class injectable antibiotic with a broad spectrum of bactericidal Gram-negative and Gram-positive activity, including activity against most contemporary MDR strains where current therapeutic choices are severely limited. ZTI-01ZOLYD, or IV Fosfomycin, is bactericidal and inhibits bacterial cell wall biogenesis by inactivating the enzyme UDP-N-acetylglucosamine-3-enol-pyruvyl transferase, also known as MurA. As on Aug.2017, ZOLYD is in Phase III trials for the treatment of cUTI, including acute pyelonephritis. The other indications for cUTI are cIAI, ABSSSI, HABPVABP, and others.
Zavante's top competitors include Spero Therapeutics, Paratek Pharma and Cempra.
Zavante offers ZOLYD and Clinical Trials Services.
Zavante has 4 investors. Key investors include Nabriva, Frazier Healthcare Partners, Longitude Capital, and Aisling Capital.
Zavante operates through Zavante Therapeutics, Inc..
Yes. Zavante was acquired by Nabriva in July 2018.